Pharmaceutical Sponsors Increase Demand for Early-Stage Nitrosamine and Topical Performance Testing

Pharmaceutical sponsors are increasingly requesting safety, quality, and performance data earlier in the drug development process, driving a surge in demand for specialized laboratory testing services. Industry discussions at a recent BioSpace conference highlight a growing focus on nitrosamine analysis, topical performance testing, and microbiome database capabilities as companies seek to meet evolving regulatory and quality standards.

Laboratories report that sponsors now prioritize these assessments during the initial stages of research to mitigate potential risks and streamline development timelines. Specifically, the industry is seeing a heightened need for nitrosamine testing to ensure product safety, as well as increased requests for In Vitro Release Testing (IVRT) and In Vitro Permeation Testing (IVPT) to evaluate the performance of topical medications. Furthermore, the expansion of microbiome database capabilities reflects a broader effort to better understand and document the biological impact of new therapeutic candidates. These trends indicate a shift toward more rigorous, data-driven validation protocols throughout the pharmaceutical pipeline.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 25, 2026

Author

GOAI